Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Elevation Oncology	Miromatrix Medical	Adverum Biotechnologies	Aptose Biosciences	ADMA Biologics
Symbol	NASDAQ:ELEV	NASDAQ:MIRO	NASDAQ:ADVM	NASDAQ:APTO	NASDAQ:ADMA
Price Information
Current Price	$5.25	$6.74	$1.76	$2.08	$1.36
50-Day Moving Average	$7.57	$7.31	$2.07	$2.29	$1.32
52-Week Low	$4.25	$6.45	$1.69	$1.96	$1.01
52-Week High	$16.22	$16.52	$14.79	$7.20	$3.11
MarketRank™
Overall Score	2.2	1.7	2.2	2.3	2.2
Analysis Score	3.5	3.5	3.0	3.5	3.6
Community Score	4.8	5.0	4.1	4.7	4.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	2.5	3.3	1.7
Earnings & Valuation Score	1.3	0.0	1.3	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Buy	Buy
Consensus Price Target	$20.78	$22.00	$6.43	$11.00	$5.70
% Upside from Price Target	295.71% upside	226.65% upside	265.26% upside	428.85% upside	319.12% upside
Trade Information
Market Cap	$121.94 million	$136.42 million	$172.75 million	$185.01 million	$266.31 million
Beta	N/A	N/A	1.16	1.65	1.24
Average Volume	54,915	35,171	1,979,575	1,913,557	4,199,785
Sales & Book Value
Annual Revenue	N/A	N/A	$250 thousand	N/A	$42.22 million
Price / Sales	N/A	N/A	690.99	N/A	6.31
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$6.44 per share	$2.93 per share	$3.53 per share	$1.00 per share	$0.52 per share
Price / Book	N/A	N/A	0.50	N/A	2.62
Profitability
Net Income	N/A	N/A	$-117.51 million	$-55.24 million	$-75.75 million
EPS	N/A	N/A	($1.52)	($0.63)	($0.64)
Trailing P/E Ratio	0.00	0.00	N/A	N/A	N/A
Forward P/E Ratio	N/A	∞	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	-108.60%
Return on Equity (ROE)	N/A	N/A	-37.80%	-53.69%	-71.69%
Return on Assets (ROA)	N/A	N/A	-30.35%	-50.11%	-32.53%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.01	N/A	N/A	0.99
Current Ratio	17.84	17.58	13.73	11.60	5.41
Quick Ratio	17.84	17.58	13.73	11.60	1.88
Ownership Information
Institutional Ownership Percentage	80.97%	16.73%	72.93%	63.64%	32.23%
Insider Ownership Percentage	N/A	N/A	4.20%	8.41%	8.70%
Miscellaneous
Employees	8	37	167	31	407
Shares Outstanding	23.23 million	20.26 million	98.15 million	88.95 million	195.81 million
Next Earnings Date	2/11/2022 (Estimated)	2/21/2022 (Estimated)	3/7/2022 (Estimated)	3/22/2022 (Estimated)	3/24/2022 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	ADMA Biologics Inc. (NASDAQ: ADMA) Stock Forecast For 2021: Weak With A -624.64 Percent Downside marketingsentinel.com - December 7 at 7:35 PM
	Find Strong Cheap Stocks Under $10 to Buy in December finance.yahoo.com - December 7 at 7:35 PM
	ADMA Biologics, Inc. (NASDAQ:ADMA) Receives Average Recommendation of "Buy" from Analysts americanbankingnews.com - December 3 at 11:45 AM
	ADMA Biologics Inc. (ADMA) Volatility Hits 5.08% – Here Is What You Should Do stocksregister.com - December 3 at 8:59 AM
	Brokerages Expect ADMA Biologics, Inc. (NASDAQ:ADMA) Will Announce Quarterly Sales of $21.93 Million americanbankingnews.com - December 2 at 3:46 AM
	ADMA Biologics, Inc. (NASDAQ:ADMA) Expected to Announce Earnings of -$0.11 Per Share americanbankingnews.com - November 30 at 11:20 AM
	ADMA Biologics Inc. (NASDAQ: ADMA) Is Down 0.00% – Is It Capable Of A Rally? stocksregister.com - November 30 at 10:25 AM
	Is ADMA Biologics Inc. (NASDAQ: ADMA) A Good Investment For New Investors Now? stocksregister.com - November 26 at 9:38 AM
	Future Outlook And Stock Price Performance For ADMA Biologics Inc. (NASDAQ: ADMA) marketingsentinel.com - November 24 at 2:27 PM
	ADMA Biologics Inc.’s (NASDAQ: ADMA) Stock Forecast: Increase To $10.00 In A Year stocksregister.com - November 23 at 2:24 PM
	For ADMA Biologics Inc. [ADMA], Analyst sees a rise to $5. What next? dbtnews.com - November 19 at 8:04 PM
	There Is A Lot Of Upside Potential For ADMA Biologics Inc.(NASDAQ: ADMA) stocksregister.com - November 19 at 3:03 PM
	ADMA Biologics Inc. (NASDAQ: ADMA) Thursday – Up 30.82% From The Lows, What Happens Next marketingsentinel.com - November 19 at 10:02 AM
	ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors finance.yahoo.com - November 17 at 9:20 AM
	Adma Biologics Advances Plasma Collection Center Expansion Plans With Opening Of New Facility In Myrtle Beach cmlviz.com - November 16 at 1:48 PM
	Eiger BioPharmaceuticals (NASDAQ:EIGR) & ADMA Biologics (NASDAQ:ADMA) Head to Head Survey americanbankingnews.com - November 16 at 11:38 AM
	ADMA Biologics Inc. (NASDAQ: ADMA) Investors To Make Big Returns Again marketingsentinel.com - November 16 at 8:47 AM
	ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC finance.yahoo.com - November 16 at 8:47 AM
	ADMA Biologics, Inc. (NASDAQ:ADMA) Forecasted to Post Q1 2022 Earnings of ($0.07) Per Share americanbankingnews.com - November 15 at 3:02 AM
	ADMA Biologics, Inc. (NASDAQ:ADMA) Expected to Post Quarterly Sales of $21.83 Million americanbankingnews.com - November 13 at 4:56 AM
	ADMA Biologics, Inc. Expected to Post FY2021 Earnings of ($0.47) Per Share (NASDAQ:ADMA) americanbankingnews.com - November 13 at 3:02 AM
	ADMA Biologics Inc. [ADMA] Is Currently 13.57 above its 200 Period Moving Avg: What Dose This Mean? dbtnews.com - November 12 at 7:48 AM
	ADMA Biologics Inc. (NASDAQ:ADMA) Up Almost 39.47% In 1 Month, Long Term Looking Good As Well marketingsentinel.com - November 12 at 7:48 AM
	ADMA Biologics Shares Rally 15% on Strong 3Q, Upgrade >ADMA marketwatch.com - November 11 at 3:41 PM
	ADMA Biologics Shares Rise On Lower Than Expected Q3 Loss, Sales Double msn.com - November 11 at 9:44 AM

Date	Company	Brokerage	Action
11/17/2021	Aptose Biosciences	Cantor Fitzgerald	Reiterated Rating
11/12/2021	Aptose Biosciences	HC Wainwright	Boost Price Target
11/11/2021	ADMA Biologics	Raymond James	Upgrade
11/8/2021	ADMA Biologics	Cantor Fitzgerald	Initiated Coverage
10/26/2021	ADMA Biologics	Raymond James	Lower Price Target
10/12/2021	Adverum Biotechnologies	SVB Leerink	Reiterated Rating
10/8/2021	ADMA Biologics	Maxim Group	Initiated Coverage
9/20/2021	ADMA Biologics	Jefferies Financial Group	Initiated Coverage
8/12/2021	ADMA Biologics	HC Wainwright	Lower Price Target
7/30/2021	Adverum Biotechnologies	Royal Bank of Canada	Reiterated Rating
7/26/2021	ADMA Biologics	HC Wainwright	Reiterated Rating
7/23/2021	Adverum Biotechnologies	The Goldman Sachs Group	Downgrade
7/23/2021	Adverum Biotechnologies	SVB Leerink	Lower Price Target
7/23/2021	Adverum Biotechnologies	Chardan Capital	Lower Price Target
7/23/2021	Adverum Biotechnologies	Cantor Fitzgerald	Downgrade
7/20/2021	Elevation Oncology	JPMorgan Chase & Co.	Initiated Coverage
7/20/2021	Elevation Oncology	Wedbush	Initiated Coverage
7/20/2021	Elevation Oncology	SVB Leerink	Initiated Coverage
7/20/2021	Elevation Oncology	Cowen	Initiated Coverage
7/19/2021	Miromatrix Medical	Craig Hallum	Initiated Coverage
7/6/2021	ADMA Biologics	HC Wainwright	Lower Price Target
7/5/2021	Aptose Biosciences	Piper Sandler	Lower Price Target
7/1/2021	Adverum Biotechnologies	Chardan Capital	Reiterated Rating
5/10/2021	Adverum Biotechnologies	SVB Leerink	Reiterated Rating
5/5/2021	Adverum Biotechnologies	Royal Bank of Canada	Reiterated Rating
5/5/2021	Adverum Biotechnologies	Truist Securities	Reiterated Rating
5/5/2021	Adverum Biotechnologies	Chardan Capital	Reiterated Rating
5/3/2021	Adverum Biotechnologies	SVB Leerink	Downgrade
4/29/2021	Adverum Biotechnologies	Lifesci Capital	Downgrade
4/29/2021	Adverum Biotechnologies	Chardan Capital	Downgrade
4/29/2021	Adverum Biotechnologies	Truist Securities	Downgrade
4/29/2021	Adverum Biotechnologies	Truist	Downgrade
4/29/2021	Adverum Biotechnologies	SVB Leerink	Lower Price Target
4/29/2021	Adverum Biotechnologies	Royal Bank of Canada	Downgrade
4/5/2021	ADMA Biologics	Jefferies Financial Group	Reiterated Rating
3/26/2021	ADMA Biologics	Maxim Group	Reiterated Rating
3/26/2021	ADMA Biologics	Raymond James	Lower Price Target
3/24/2021	Aptose Biosciences	Oppenheimer	Boost Price Target
3/2/2021	Adverum Biotechnologies	Cantor Fitzgerald	Reiterated Rating
2/22/2021	Aptose Biosciences	Jonestrading	Initiated Coverage
1/4/2021	ADMA Biologics	HC Wainwright	Lower Price Target
12/15/2020	Adverum Biotechnologies	UBS Group	Initiated Coverage
11/12/2020	Adverum Biotechnologies	Raymond James	Upgrade
11/5/2020	Adverum Biotechnologies	Lifesci Capital	Reiterated Rating
10/20/2020	Aptose Biosciences	Canaccord Genuity	Reiterated Rating
10/19/2020	Aptose Biosciences	Cantor Fitzgerald	Initiated Coverage
10/1/2020	ADMA Biologics	Raymond James	Boost Price Target
9/22/2020	Aptose Biosciences	Alliance Global Partners	Initiated Coverage
8/26/2020	Adverum Biotechnologies	Raymond James	Reiterated Rating
8/11/2020	Adverum Biotechnologies	SVB Leerink	Boost Price Target
8/10/2020	Adverum Biotechnologies	Piper Sandler	Boost Price Target
8/6/2020	ADMA Biologics	HC Wainwright	Reiterated Rating
8/6/2020	ADMA Biologics	Oppenheimer	Initiated Coverage
7/28/2020	ADMA Biologics	HC Wainwright	Reiterated Rating
6/23/2020	Aptose Biosciences	Piper Sandler	Reiterated Rating
6/14/2020	Aptose Biosciences	Oppenheimer	Initiated Coverage
6/12/2020	Aptose Biosciences	Maxim Group	Initiated Coverage
6/12/2020	Aptose Biosciences	HC Wainwright	Reiterated Rating
5/22/2020	ADMA Biologics	Maxim Group	Initiated Coverage
5/22/2020	ADMA Biologics	HC Wainwright	Reiterated Rating
5/7/2020	ADMA Biologics	Oppenheimer	Lower Price Target
4/27/2020	Aptose Biosciences	HC Wainwright	Reiterated Rating
3/16/2020	ADMA Biologics	HC Wainwright	Lower Price Target
3/4/2020	Aptose Biosciences	Canaccord Genuity	Reiterated Rating
2/20/2020	Aptose Biosciences	Maxim Group	Initiated Coverage
2/6/2020	Aptose Biosciences	HC Wainwright	Boost Price Target
1/9/2020	Aptose Biosciences	Piper Sandler	Initiated Coverage
1/8/2020	ADMA Biologics	HC Wainwright	Reiterated Rating
11/20/2019	ADMA Biologics	HC Wainwright	Reiterated Rating
10/21/2019	ADMA Biologics	Maxim Group	Set Price Target
8/27/2019	ADMA Biologics	Maxim Group	Reiterated Rating
8/12/2019	ADMA Biologics	Dawson James	Downgrade
8/7/2019	Aptose Biosciences	HC Wainwright	Lower Price Target
5/23/2019	Aptose Biosciences	Roth Capital	Reiterated Rating
4/2/2019	Aptose Biosciences	HC Wainwright	Set Price Target
3/22/2019	Aptose Biosciences	HC Wainwright	Set Price Target
3/1/2019	Aptose Biosciences	Royal Bank of Canada	Initiated Coverage
1/25/2019	Aptose Biosciences	Citigroup	Initiated Coverage
1/24/2019	Aptose Biosciences	Oppenheimer	Initiated Coverage
12/13/2018	Aptose Biosciences	HC Wainwright	Set Price Target

(Data available from 12/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources